Update on the Management of High-Risk Penetrating Keratoplasty

[1]  D. Larkin,et al.  The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and Failure , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  P. Majmudar,et al.  Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study , 2016, Cornea.

[3]  F. Ziaei,et al.  Systemic cyclosporine and corneal transplantation , 2016, International Ophthalmology.

[4]  J. Szaflik,et al.  Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5]  A. Sugar.  The Importance of Corneal Endothelial Cell Survival After Endothelial Keratoplasty. , 2015, JAMA ophthalmology.

[6]  S. Cook,et al.  Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression , 2015, Cornea.

[7]  H. Nian,et al.  Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells. , 2015, International journal of ophthalmology.

[8]  J. Niederkorn,et al.  Severing Corneal Nerves in One Eye Induces Sympathetic Loss of Immune Privilege and Promotes Rejection of Future Corneal Allografts Placed in Either Eye , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  R. D. Stulting,et al.  Prevention and Treatment of Corneal Graft Rejection: Current Practice Patterns of the Cornea Society (2011) , 2015, Cornea.

[10]  D. Roelen,et al.  Matching for Human Leukocyte Antigens (HLA) in corneal transplantation – To do or not to do , 2015, Progress in Retinal and Eye Research.

[11]  R. Dana,et al.  VEGF-trap Aflibercept Significantly Improves Long-term Graft Survival in High-risk Corneal Transplantation , 2015, Transplantation.

[12]  R. Beck,et al.  Factors associated with corneal graft survival in the cornea donor study. , 2015, JAMA ophthalmology.

[13]  M. Ziaei,et al.  Topical Cyclosporine in Corneal Transplantation , 2015, Cornea.

[14]  E. Balestrazzi,et al.  Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival , 2015, International Ophthalmology.

[15]  N. Gabrić,et al.  Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[16]  J. Shimazaki,et al.  Efficacy and Safety of Systemic Tacrolimus in High-Risk Penetrating Keratoplasty After Graft Failure With Systemic Cyclosporine , 2014, Cornea.

[17]  Mark J Mannis,et al.  Corneal Graft Rejection 10 Years After Penetrating Keratoplasty in the Cornea Donor Study , 2014, Cornea.

[18]  Yasin Cinar,et al.  Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model , 2014, Cutaneous and ocular toxicology.

[19]  D. Papaconstantinou,et al.  The Effect of Subconjunctival Ranibizumab on Corneal and Anterior Segment Neovascularization: Study on an Animal Model , 2014, European journal of ophthalmology.

[20]  C. Cursiefen,et al.  Topical Ranibizumab inhibits inflammatory corneal hem‐ and lymphangiogenesis , 2014, Acta ophthalmologica.

[21]  F. Yu,et al.  Outcomes After DSEK in 101 Eyes With Previous Trabeculectomy and Tube Shunt Implantation , 2014, Cornea.

[22]  P. Hamrah,et al.  Corneal Allograft Rejection: Immunopathogenesis to Therapeutics , 2013, Journal of clinical & cellular immunology.

[23]  K. Tsubota,et al.  Keratoplasty Postoperative Treatment Update , 2013, Cornea.

[24]  A. Leonardi.  Management of Vernal Keratoconjunctivitis , 2013, Ophthalmology and Therapy.

[25]  T. Ritter,et al.  Gene Therapy Approaches to Prevent Corneal Graft Rejection: Where Do We Stand? , 2013, Ophthalmic Research.

[26]  C. Rapuano,et al.  Long-term Results of Keratoplasty in Patients With Herpes Zoster Ophthalmicus , 2013, Cornea.

[27]  S. Dundar,et al.  Short-term topical bevacizumab in the treatment of stable corneal neovascularization. , 2013, American journal of ophthalmology.

[28]  J. Rakic,et al.  Sunitinib inhibits inflammatory corneal lymphangiogenesis. , 2013, Investigative ophthalmology & visual science.

[29]  J. Zhao,et al.  A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study. , 2013, Ophthalmology.

[30]  S. Theodoropoulou,et al.  Vascular Endothelial Growth Factor Inhibitors for Treatment of Corneal Neovascularization: A Meta-Analysis , 2013, Cornea.

[31]  O. Sandali,et al.  Long-term rejection incidence and reversibility after penetrating and lamellar keratoplasty. , 2013, American journal of ophthalmology.

[32]  Jun-Sub Choi,et al.  Effects of subconjunctival ranibizumab in a presensitized rat model of corneal graft. , 2013, Experimental eye research.

[33]  B. Ambati,et al.  Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model. , 2012, Investigative ophthalmology & visual science.

[34]  Purendra Bhasin,et al.  A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab. , 2012, Cornea.

[35]  R. D. Stulting,et al.  Effect of Donor and Recipient Factors on Corneal Graft Rejection , 2012, Cornea.

[36]  F. Kruse,et al.  Angioregressive Pretreatment of Mature Corneal Blood Vessels Before Keratoplasty: Fine-Needle Vessel Coagulation Combined With Anti-VEGFs , 2012, Cornea.

[37]  R. Dana,et al.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). , 2012, The ocular surface.

[38]  Thomas Gaujoux,et al.  Long-term results of deep anterior lamellar versus penetrating keratoplasty. , 2012, Ophthalmology.

[39]  D. Ruiz-Casas,et al.  Efficacy of Bevacizumab Against Interface Neovascularization After Deep Anterior Lamellar Keratoplasty , 2012, Cornea.

[40]  T. Ritter,et al.  Role of Lentivirus‐Mediated Overexpression of Programmed Death‐Ligand 1 on Corneal Allograft Survival , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[41]  A. Joussen,et al.  Efficacy of Postoperative Immunosuppression After Keratoplasty in Herpetic Keratitis , 2011, Cornea.

[42]  M. Hashemian.  Deep intrastromal bevacizumab injection for management of corneal stromal vascularization following deep anterior lamellar keratoplasty , 2011 .

[43]  A. Foroutan,et al.  Perilimbal Bevacizumab Injection for Interface Neovascularization After Deep Anterior Lamellar Keratoplasty , 2010, Cornea.

[44]  D. Larkin,et al.  Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. , 2010, American journal of ophthalmology.

[45]  E. Holland,et al.  Large-Diameter Penetrating Keratoplasty: Indications and Outcomes , 2010, Cornea.

[46]  Z. Haskova,et al.  Local Treatment With Alpha-Melanocyte Stimulating Hormone Reduces Corneal Allorejection , 2009, Transplantation.

[47]  Claus Cursiefen,et al.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[48]  R. Dana,et al.  Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. , 2009, Archives of ophthalmology.

[49]  R. Dana,et al.  ‘Chimeric’ Grafts Assembled from Multiple Allodisparate Donors Enjoy Enhanced Transplant Survival , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[50]  N. Sharma,et al.  Topical cyclosporine. , 2009, Ophthalmology.

[51]  S. Kaufman,et al.  Long-term Use of Topical Tacrolimus (FK506) in High-risk Penetrating Keratoplasty , 2008, Cornea.

[52]  K. Maruyama,et al.  Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. , 2008, Archives of ophthalmology.

[53]  A. Mearza,et al.  Uses and safety profile of ciclosporin in ophthalmology. , 2008, Expert opinion on drug safety.

[54]  J. Schwartzkopff,et al.  [Basiliximab following penetrating risk-keratoplasty--a prospective randomized pilot study]. , 2008, Klinische Monatsblatter fur Augenheilkunde.

[55]  M. Dana,et al.  Graft failure IV. Immunologic mechanisms of corneal transplant rejection , 2008, International Ophthalmology.

[56]  A. Panda,et al.  Corneal graft rejection. , 2007, Survey of ophthalmology.

[57]  Björn Bachmann,et al.  Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. , 2007, Investigative ophthalmology & visual science.

[58]  H. Volk,et al.  Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival , 2007, Gene Therapy.

[59]  M. Dana,et al.  Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival. , 2007, Investigative ophthalmology & visual science.

[60]  R. Dana,et al.  Corneal antigen-presenting cells. , 2007, Chemical immunology and allergy.

[61]  V. Shanmuganathan,et al.  Tacrolimus immunosuppression in high-risk corneal grafts , 2006, British Journal of Ophthalmology.

[62]  Shen‐guo Wang,et al.  Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. , 2006, Investigative ophthalmology & visual science.

[63]  T. Reinhard,et al.  Current Systemic Immunosuppressive Strategies in Penetrating Keratoplasty , 2006 .

[64]  B. Seitz,et al.  Systemic mycophenolate mofetil avoids immune reactions in penetrating high‐risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study * , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[65]  D. Böhringer,et al.  Immunosuppression with Cyclosporine A and Mycophenolate Mofetil After Penetrating High-Risk Keratoplasty: A Retrospective Study , 2005, Transplantation.

[66]  M. Thiel,et al.  Local or short‐term systemic costimulatory molecule blockade prolongs rat corneal allograft survival , 2005, Clinical & experimental ophthalmology.

[67]  M. Dana,et al.  Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity , 2004, Nature Medicine.

[68]  J. Forrester,et al.  Lymph node removal enhances corneal graft survival in mice at high risk of rejection , 2004, BMC ophthalmology.

[69]  M. Isobe,et al.  The role of cell adhesion molecules in allograft rejection after penetrating keratoplasty in mice. Clinical and immunohistochemical study , 1996, Graefe's Archive for Clinical and Experimental Ophthalmology.

[70]  O. Beltaief,et al.  [Penetrating keratoplasty in children]. , 2003, La Tunisie medicale.

[71]  M. Thiel,et al.  The potential of antibody‐based immunosuppressive agents for corneal transplantation , 2003, Immunology and cell biology.

[72]  J. Streilein,et al.  The role of minor histocompatibility alloantigens in penetrating keratoplasty. , 2003, Developments in ophthalmology.

[73]  Minhua H. Wang,et al.  Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection. , 2002, Yan ke xue bao = Eye science.

[74]  U. Rehany,et al.  The conundrum of death, dying and organ donation , 2002, The British journal of ophthalmology.

[75]  R. Dana,et al.  Draining Lymph Nodes of Corneal Transplant Hosts Exhibit Evidence for Donor Major Histocompatibility Complex (MHC) Class II–positive Dendritic Cells Derived from MHC Class II–negative Grafts , 2002, The Journal of experimental medicine.

[76]  Mark D. Aupperlee,et al.  Identification of androgen receptors in rabbit lacrimal gland by immunohistochemsitry. , 2000, Advances in experimental medicine and biology.

[77]  M. Dana,et al.  Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in the conjunctiva--a potential link between lymphangiogenesis and leukocyte trafficking on the ocular surface. , 2002, Advances in experimental medicine and biology.

[78]  E. Godehardt,et al.  Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[79]  S. Klebe,et al.  PROLONGATION OF SHEEP CORNEAL ALLOGRAFT SURVIVAL BY EX VIVO TRANSFER OF THE GENE ENCODING INTERLEUKIN-101 , 2001, Transplantation.

[80]  J. Naor,et al.  Corneal Graft Outcome Study , 2001, Cornea.

[81]  U. Rehany,et al.  The profile of repeated corneal transplantation. , 2001, Ophthalmology.

[82]  M. Araie,et al.  Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. , 1999, Japanese journal of ophthalmology.

[83]  S. Klebe,et al.  Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001; 71: 1214. , 2001, Transplantation.

[84]  B. Wittig,et al.  Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[85]  H. Volk,et al.  Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4 , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[86]  Santa Jeremy Ono,et al.  Differential chemokine gene expression in corneal transplant rejection. , 1999, Investigative ophthalmology & visual science.

[87]  B. Gebhardt,et al.  Protection of corneal allografts by CTLA4-Ig. , 1999, Cornea.

[88]  G A Knoll,et al.  Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials , 1999, BMJ.

[89]  H. Suzuki,et al.  Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. , 1998, Transplantation.

[90]  J. Niederkorn,et al.  Oral immunisation as a strategy for enhancing corneal allograft survival , 1997, The British journal of ophthalmology.

[91]  M. Isobe,et al.  Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. , 1997, Experimental eye research.

[92]  N. Ehlers,et al.  Significant effect of high-resolution HLA-DRB1 matching in high-risk corneal transplantation. , 1996, Transplantation.

[93]  B. Ksander,et al.  Minor H, rather than MHC, alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice. , 1996, Transplant immunology.

[94]  S. Gore,et al.  HLA‐DR MATCHING IN CORNEAL TRANSPLANTATION: SYSTEMATIC REVIEW OF PUBLISHED EVIDENCE , 1995, Transplantation.

[95]  J. C. Hill,et al.  Systemic cyclosporine in high-risk keratoplasty: Long-term results , 1995, Eye.

[96]  S. Gore,et al.  Negative effect of HLA-DR matching on corneal transplant rejection. , 1995, Transplantation proceedings.

[97]  J. Streilein,et al.  Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye , 1995, Eye.

[98]  R. D. Stulting,et al.  Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. , 1994, Ophthalmology.

[99]  N. Barney,et al.  A Prospective Randomized Trial of Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis , 1994, Cornea.

[100]  J. Hill,et al.  Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. , 1994, Ophthalmology.

[101]  R. Nussenblatt,et al.  Expression of Cell Adhesion Molecules in Corneal Graft Failure , 1993, Cornea.

[102]  J. Sugar,et al.  Topical Cyclosporin A in the Treatment of Anterior Segment Inflammatory Disease , 1993, Cornea.

[103]  The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. , 1992, Archives of ophthalmology.

[104]  R. Guymer,et al.  Monoclonal antibody to ICAM-1 prolongs murine heterotopic corneal allograft survival. , 1991, Australian and New Zealand journal of ophthalmology.

[105]  S. Wilson,et al.  Graft failure after penetrating keratoplasty. , 1990, Survey of ophthalmology.

[106]  M. Belin,et al.  Topical cyclosporine in high-risk corneal transplants. , 1989, Ophthalmology.

[107]  R. D. Stulting,et al.  Effect of donor epithelium on corneal transplant survival. , 1988, Ophthalmology.

[108]  R. D. Stulting,et al.  Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. , 1987, Ophthalmology.

[109]  Y. Pouliquen,et al.  [Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results]. , 1987, Journal francais d'ophtalmologie.

[110]  W. Vaughn,et al.  Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. , 1986, The New England journal of medicine.

[111]  R. D. Stulting,et al.  Penetrating keratoplasty in children. , 1984, Ophthalmology.

[112]  R. Poirier,et al.  Corneal allograft reaction and its relationship to suture site neovascularization. , 1977, Ophthalmic surgery.

[113]  M. Clement,et al.  PREVENTION AND TREATMENT , 1944 .